Immune checkpoint blockade has been a pivotal development in the management of advanced
non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved …

In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC)
patients, one of the most relevant breakthroughs is represented by targeted therapies. …

Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for
immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative …

Peripheral blood inflammatory indices, like the neutrophil-to-lymphocyte ratio (NLR), may
reflect the host's pro-inflammatory status and systemic immune response to cancer-related …

Background The early crossing of survival curves in randomised clinical trials (RCTs) with
immune checkpoint blockers suggests an excess of mortality in the first months of treatment. …

Background Second-line immunotherapy (IO) has shown an overall survival benefit. However,
only 18% to 20% of patients with advanced non–small-cell lung cancer (aNSCLC) will …

Objectives Most trials with Immune Checkpoint Inhibitors (ICIs) for Non-Small Cell Lung
Cancer (NSCLC) included only small subgroups of patients aged ≥65. As NSCLC is often …

Purpose of review To describe the biological rationale of peripheral blood cells (PBC)–derived
inflammatory indexes and assess the related prognostic scores for patients with …

Recently, a wide spectrum of artificial intelligence (AI)–based applications in the broader
categories of digital pathology, biomarker development, and treatment have been explored. In …

Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most frequent …